Showing 1 - 5 results of 5 for search 'Helen X. Chen', query time: 0.02s Refine Results
  1. 1
    Ocular adverse events in PD-1 and PD-L1 inhibitors

    Ocular adverse events in PD-1 and PD-L1 inhibitors by James Murray, Howard Streicher, Elad Sharon, LeAnne Young, Shanda Finnigan, H Nida Sen, Helen X Chen

    Published 2021-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort

    Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort by Howard Streicher, Elad Sharon, Razelle Kurzrock, Young Kwang Chae, Benjamin Tan, Megan Othus, Christine McLeod, Charles Blanke, Helen X Chen, Sandip P Patel, Gabby Lopez, Tridu Huynh, Timothy Kuzel, Christopher W Ryan

    Published 2024-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

    A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the... by Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic, Sajeve S. Thomas, William R. Robinson III, Hye Sung Kim, Liam Il‐Young Chung, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

    Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce by Mario Sznol, Roberta Zappasodi, Margaret K. Callahan, Dung T. Le, Robert L. Ferris, James L. Gulley, Charles G. Drake, Ryan J. Sullivan, Elad Sharon, Hussein A. Tawbi, Harriet M. Kluger, Janis M. Taube, Shilpa Gupta, Suzanne L. Topalian, Edward Cha, Michael A. Postow, Vassiliki A. Papadimitrakopoulou, Maria L. Ascierto, Michaela Bowden, Helen X. Chen, David M. Feltquate, Rachel W. Humphrey, Theresa M. LaVallee, Vanessa M. Hubbard-Lucey, Eric H. Rubin

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort

    Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort by Ignacio I Wistuba, Jianhua Zhang, Anup Kasi, Hong Chen, Seunghee Kim-Schulze, Holden T Maecker, Elad Sharon, Razelle Kurzrock, Sacha Gnjatic, Young Kwang Chae, Jiexin Zhang, Jianjun Zhang, Sandip Pravin Patel, Cara L Haymaker, Megan Othus, Charles Blanke, Edwin Parra, Gheath Al-Atrash, Caroline Duault, J Jack Lee, Helen X Chen, Edgar Gonzalez-Kozlova, Dzifa Yawa Duose, Luisa Solis Soto, Ganiraju Manyam, Christopher W Ryan, Jillian Fisher, Bhavana Konda, Mark Walshauser, Caddie Laberiano Fernandez, Raja Luthra, Christine M Magner

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: